Sierra Oncology shared positive topline results from the company’s study on the effectiveness of momelotinib to treat patients with myelofibrosis.

AC Immune’s stock fell 9 percent on the news that the company’s Phase II Lauriet study of the investigational anti-Tau monoclonal antibody semorinemab in mild-to-moderate Alzheimer’s disease (AD) did not meet all endpoints.

Angion Biomedica and Vifor Pharma announced that their Phase III trial on ANG-3777 for renal transplant patients did not meet the study’s primary and secondary endpoints.

The latest results from SURPASS-4, the longest and largest completed SURPASS trial to date, showed consistent activity in maintaining A1C and weight control in the almost two years the study ran. SURPASS-4 is part of the Phase III trial evaluating tirzepatide as a potential treatment for type 2 diabetes. 

According to a California WARN notice, Sanofi is shuttering Principia Biopharma’s laboratories in San Francisco and laying off about three dozen employees after the Phase III PEGASUS trial failure of rilzabrutinib for pemphigus.

Paris-based Sanofi announced that the company’s Phase III PEGASUS clinical trial of rilzabrutinib for pemphigus failed to hit the primary or key secondary endpoints. Sanofi picked up the drug when the company acquired South San Francisco-based Principia Biopharma in August 2020 for $3.68 billion.

Belgium-based Bone Therapeutics’ Phase III osteoarthritis study using the company’s enhanced viscosupplement JTA-004 failed to meet primary and critical secondary endpoints.

Amneal Pharmaceuticals Inc announced positive topline results from the pivotal Phase 3 RISE-PD clinical trial that evaluated the novel formulation, IPX-203, in patients with Parkinson’s disease (PD) who have motor fluctuations.

Eli Lilly announced the success of the global health care company’s clinical trial on lebrikizumab as a treatment for people diagnosed with moderate to severe atopic dermatitis (AD). 

International eye-care products manufacturer Allergan announced positive outcomes from the AbbVie company’s Phase 3 study of a new treatment for presbyopia, as the ophthalmic solution AGN-190584 met primary and key secondary endpoints.